Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI study of simnotrelvir/ritonavir with itraconazole, rifampicin, and midazolam
NCT05665647Phase 1Completed
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Dec 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of simnotrelvir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Maximum Plasma Concentration (Cmax) of SIM0417 at Day 14, Area Under the Curve (AUC) of SIM0417 at Day 14 and 4 more. Started Dec 2022; status: completed.
02
Drugs
simnotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05665647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05665647.